Loading stock data…
Arcutis Biotherapeutics, Inc. (ARQT)
$24.30+0.40 (+1.67%)
Market OpenUpdated 12:53 PM EDT
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Arcutis Biotherapeutics, Inc. in the Healthcare sector is trading at $23.90 with a market capitalization of $3.0B. Wall Street consensus targets $36.88 (8 analysts), implying a +54.3% move over the next 12 months. The stock is currently 25% below its 52-week high of $31.77, remaining 6.6% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +54.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 34) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $105.40M↓ | $129.50M↑ | $99.22M↑ | $81.50M↑ | $65.85M |
| Gross Profit | $95.61M↓ | $117.81M↑ | $90.53M↑ | $74.01M↑ | $57.02M |
| Operating Income | -$9.09M↓ | $18.39M↑ | $8.53M↑ | -$14.61M↑ | -$24.53M |
| Net Income | -$11.29M↓ | $17.39M↑ | $7.41M↑ | -$15.89M↑ | -$25.06M |
Peer Comparison
JNJUNHPFE
Fundamentals
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.97B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
107.55
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.53
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
12.93%
Volume
Today's trading volume
2.00M
Recent News
Here's Why You Should Add ARQT Stock to Your Portfolio Now
Arcutis raises its 2026 revenue guidance as Zoryve gains momentum, expands into younger patients and advances potential new indications.
Arcutis Biotherapeutics (ARQT) Faces A Valuation Test, Is It Still A Bargain?
Arcutis Biotherapeutics Stock Performance Snapshot Arcutis Biotherapeutics (ARQT) has drawn investor attention after recent share price moves, with the stock down about 12% over the past month but up roughly 16% over the past 3 months. The company, which focuses on dermatological treatments such as its lead product ZORYVE, now carries a market value of about US$3.16b and recently closed at US$24.87 as of 25 August 2026. Looking at the bigger picture, Arcutis Biotherapeutics has seen mixed...
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen
Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.
5 Biotech Stocks Worth Adding to Your Portfolio Now
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, RGEN, IOVA, ARQT and PGEN in this volatile sector.
Arcutis (ARQT) Q2 2026 Earnings Call Transcript
ZORYVE franchise revenue surged 59% year-over-year, driving profitability.